Back to companies

RegenxBio Inc: Segment Analysis

Want to continue viewing company data?

Sign up for exclusive competitve intelligence.

Create account

Business Description

RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC, is an early stage biotechnology company that produces therapeutic proteins or antibodies for the treatment of retinal diseases, metabolic diseases, and neurodegenerative diseases. It reports its operations under single segment.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

R&D Overview

RegenxBio works in collaboration with its strategic partners to conduct research to develop therapeutic antibodies, proteins, and gene editing. In FY2020, the company incurred US$166.3 million on its R&D expenses, which grew 33.9% YoY. Its R&D programs focuses on developing treatments for Retinitis Pigmentosa (RP), metabolic diseases, homozygous familial hypercholesterolemia (HoFH) caused by LDLR mutations, neurodegenerative diseases, mucopolysaccharidosis type I (MPS I) caused by autosomal recessive IDUA mutations, and MPS II caused by X-linked recessive IDS mutations, and to advance its NAV technology platform. As of December 31, 2020, the company had over 100 patents and patent applications spanning its NAV vectors, including composition of matter claims for AAV7, AAV8, AAV9 and AAVrh10, and methods for their manufacture and therapeutic uses. Further, the company intends to expand this robust patent portfolio. As of December 31, 2020, its licensed patent portfolio included five European patents and thirteen issued US patents associated with the AAV7, AAV8, AAV9 and AAVrh10 vectors and their uses and these patents are scheduled to expire between 2036 and 2038.